Researchers track Long-Term risks of viral cancer therapy

NCT ID NCT06887348

Recruiting now Knowledge-focused Sponsor: Replimune, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma melanoma metastatic melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR HEPATOCELLULAR CARCINOMA MELANOMA METASTATIC MELANOMA

Contacts and locations

Locations

Tasman Oncology Research
RECRUITING

Southport, Queensland, 4215, Australia
UC San Diego Moores Cancer Center
RECRUITING

La Jolla, California, 92093-0698, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.